Folate  ||| S:0 E:7 ||| NNP
in  ||| S:7 E:10 ||| IN
depression ||| S:10 E:20 ||| NN
:  ||| S:20 E:22 ||| :
efficacy ||| S:22 E:30 ||| CD
,  ||| S:30 E:32 ||| ,
safety ||| S:32 E:38 ||| NN
,  ||| S:38 E:40 ||| ,
differences  ||| S:40 E:52 ||| NNS
in  ||| S:52 E:55 ||| IN
formulations ||| S:55 E:67 ||| NNS
,  ||| S:67 E:69 ||| ,
and  ||| S:69 E:73 ||| CC
clinical  ||| S:73 E:82 ||| JJ
issues  ||| S:82 E:89 ||| NNS
Supplementation  ||| S:89 E:105 ||| NNP
with  ||| S:105 E:110 ||| IN
folate  ||| S:110 E:117 ||| NNS
may  ||| S:117 E:121 ||| MD
help  ||| S:121 E:126 ||| VB
reduce  ||| S:126 E:133 ||| VB
depressive  ||| S:133 E:144 ||| JJ
symptoms ||| S:144 E:152 ||| NNS
.  ||| S:152 E:154 ||| .
Folate ||| S:154 E:160 ||| NNP
,  ||| S:160 E:162 ||| ,
a  ||| S:162 E:164 ||| DT
naturally  ||| S:164 E:174 ||| RB
occurring  ||| S:174 E:184 ||| VBG
B  ||| S:184 E:186 ||| NNP
vitamin ||| S:186 E:193 ||| NN
,  ||| S:193 E:195 ||| ,
is  ||| S:195 E:198 ||| VBZ
needed  ||| S:198 E:205 ||| VBN
in  ||| S:205 E:208 ||| IN
the  ||| S:208 E:212 ||| DT
brain  ||| S:212 E:218 ||| NN
for  ||| S:218 E:222 ||| IN
the  ||| S:222 E:226 ||| DT
synthesis  ||| S:226 E:236 ||| NN
of  ||| S:236 E:239 ||| IN
norepinephrine ||| S:239 E:253 ||| NN
,  ||| S:253 E:255 ||| ,
serotonin ||| S:255 E:264 ||| NN
,  ||| S:264 E:266 ||| ,
and  ||| S:266 E:270 ||| CC
dopamine ||| S:270 E:278 ||| NN
.  ||| S:278 E:280 ||| .
Three  ||| S:280 E:286 ||| CD
forms  ||| S:286 E:292 ||| NNS
of  ||| S:292 E:295 ||| IN
folate  ||| S:295 E:302 ||| NNS
are  ||| S:302 E:306 ||| VBP
commonly  ||| S:306 E:315 ||| RB
used ||| S:315 E:319 ||| VBN
:  ||| S:319 E:321 ||| :
folic  ||| S:321 E:327 ||| JJ
acid ||| S:327 E:331 ||| NN
,  ||| S:331 E:333 ||| ,
5-methyltetrahydrofolate  ||| S:333 E:358 ||| NNP
( ||| S:358 E:359 ||| -LRB-
5-MTHF ||| S:359 E:365 ||| NNP
)  ||| S:365 E:367 ||| -RRB-
( ||| S:367 E:368 ||| -LRB-
also  ||| S:368 E:373 ||| RB
known  ||| S:373 E:379 ||| VBN
as  ||| S:379 E:382 ||| IN
methylfolate  ||| S:382 E:395 ||| NN
and  ||| S:395 E:399 ||| CC
L-methylfolate ||| S:399 E:413 ||| NNP
) ||| S:413 E:414 ||| -RRB-
,  ||| S:414 E:416 ||| ,
and  ||| S:416 E:420 ||| CC
folinic  ||| S:420 E:428 ||| JJ
acid ||| S:428 E:432 ||| NN
.  ||| S:432 E:434 ||| .
Some  ||| S:434 E:439 ||| DT
forms  ||| S:439 E:445 ||| NNS
may  ||| S:445 E:449 ||| MD
be  ||| S:449 E:452 ||| VB
more  ||| S:452 E:457 ||| JJR
bioavailable  ||| S:457 E:470 ||| NN
than  ||| S:470 E:475 ||| IN
others  ||| S:475 E:482 ||| NNS
in  ||| S:482 E:485 ||| IN
patients  ||| S:485 E:494 ||| NNS
with  ||| S:494 E:499 ||| IN
a  ||| S:499 E:501 ||| DT
genetic  ||| S:501 E:509 ||| JJ
polymorphism  ||| S:509 E:522 ||| NN
and  ||| S:522 E:526 ||| CC
in  ||| S:526 E:529 ||| IN
those  ||| S:529 E:535 ||| DT
who  ||| S:535 E:539 ||| WP
take  ||| S:539 E:544 ||| VBP
particular  ||| S:544 E:555 ||| JJ
medications  ||| S:555 E:567 ||| NN
or  ||| S:567 E:570 ||| CC
use  ||| S:570 E:574 ||| NN
alcohol ||| S:574 E:581 ||| NN
.  ||| S:581 E:583 ||| .
Folic  ||| S:583 E:589 ||| JJ
acid  ||| S:589 E:594 ||| NN
augmentation  ||| S:594 E:607 ||| NN
in  ||| S:607 E:610 ||| IN
depressed  ||| S:610 E:620 ||| JJ
patients  ||| S:620 E:629 ||| NNS
may  ||| S:629 E:633 ||| MD
reduce  ||| S:633 E:640 ||| VB
residual  ||| S:640 E:649 ||| JJ
symptoms ||| S:649 E:657 ||| NNS
.  ||| S:657 E:659 ||| .
The  ||| S:659 E:663 ||| DT
5-MTHF  ||| S:663 E:670 ||| JJ
formulation  ||| S:670 E:682 ||| NN
indicated  ||| S:682 E:692 ||| VBD
efficacy  ||| S:692 E:701 ||| VBN
as  ||| S:701 E:704 ||| IN
adjunctive  ||| S:704 E:715 ||| JJ
therapy  ||| S:715 E:723 ||| NN
or  ||| S:723 E:726 ||| CC
monotherapy  ||| S:726 E:738 ||| NN
in  ||| S:738 E:741 ||| IN
reducing  ||| S:741 E:750 ||| VBG
depressive  ||| S:750 E:761 ||| JJ
symptoms  ||| S:761 E:770 ||| NNS
in  ||| S:770 E:773 ||| IN
patients  ||| S:773 E:782 ||| NNS
with  ||| S:782 E:787 ||| IN
normal  ||| S:787 E:794 ||| JJ
and  ||| S:794 E:798 ||| CC
low  ||| S:798 E:802 ||| JJ
folate  ||| S:802 E:809 ||| JJ
levels ||| S:809 E:815 ||| NNS
,  ||| S:815 E:817 ||| ,
improving  ||| S:817 E:827 ||| VBG
cognitive  ||| S:827 E:837 ||| JJ
function  ||| S:837 E:846 ||| NN
and  ||| S:846 E:850 ||| CC
reducing  ||| S:850 E:859 ||| VBG
depressive  ||| S:859 E:870 ||| JJ
symptoms  ||| S:870 E:879 ||| NNS
in  ||| S:879 E:882 ||| IN
elderly  ||| S:882 E:890 ||| JJ
patients  ||| S:890 E:899 ||| NNS
with  ||| S:899 E:904 ||| IN
dementia  ||| S:904 E:913 ||| NN
and  ||| S:913 E:917 ||| CC
folate  ||| S:917 E:924 ||| JJ
deficiency ||| S:924 E:934 ||| NN
,  ||| S:934 E:936 ||| ,
and  ||| S:936 E:940 ||| CC
reducing  ||| S:940 E:949 ||| VBG
depressive  ||| S:949 E:960 ||| NNS
and  ||| S:960 E:964 ||| CC
somatic  ||| S:964 E:972 ||| JJ
symptoms  ||| S:972 E:981 ||| NNS
in  ||| S:981 E:984 ||| IN
patients  ||| S:984 E:993 ||| NNS
with  ||| S:993 E:998 ||| IN
depression  ||| S:998 E:1009 ||| NN
and  ||| S:1009 E:1013 ||| CC
alcoholism ||| S:1013 E:1023 ||| NN
.  ||| S:1023 E:1025 ||| .
Adjunctive  ||| S:1025 E:1036 ||| JJ
folinic  ||| S:1036 E:1044 ||| JJ
acid  ||| S:1044 E:1049 ||| NN
reduced  ||| S:1049 E:1057 ||| VBD
depressive  ||| S:1057 E:1068 ||| JJ
symptoms  ||| S:1068 E:1077 ||| NNS
in  ||| S:1077 E:1080 ||| IN
patients  ||| S:1080 E:1089 ||| NNS
who  ||| S:1089 E:1093 ||| WP
were  ||| S:1093 E:1098 ||| VBD
partially  ||| S:1098 E:1108 ||| RB
responsive  ||| S:1108 E:1119 ||| JJ
or  ||| S:1119 E:1122 ||| CC
nonresponsive  ||| S:1122 E:1136 ||| JJ
to  ||| S:1136 E:1139 ||| TO
a  ||| S:1139 E:1141 ||| DT
selective  ||| S:1141 E:1151 ||| JJ
serotonin  ||| S:1151 E:1161 ||| JJ
reuptake  ||| S:1161 E:1170 ||| JJ
inhibitor ||| S:1170 E:1179 ||| NN
.  ||| S:1179 E:1181 ||| .
Evidence  ||| S:1181 E:1190 ||| NN
for  ||| S:1190 E:1194 ||| IN
the  ||| S:1194 E:1198 ||| DT
efficacy  ||| S:1198 E:1207 ||| NN
of  ||| S:1207 E:1210 ||| IN
folate  ||| S:1210 E:1217 ||| NN
in  ||| S:1217 E:1220 ||| IN
improving  ||| S:1220 E:1230 ||| VBG
cognitive  ||| S:1230 E:1240 ||| JJ
symptoms  ||| S:1240 E:1249 ||| NNS
is  ||| S:1249 E:1252 ||| VBZ
equivocal ||| S:1252 E:1261 ||| VBN
,  ||| S:1261 E:1263 ||| ,
but  ||| S:1263 E:1267 ||| CC
most  ||| S:1267 E:1272 ||| JJS
studies  ||| S:1272 E:1280 ||| NNS
used  ||| S:1280 E:1285 ||| VBN
folic  ||| S:1285 E:1291 ||| JJ
acid ||| S:1291 E:1295 ||| NN
.  ||| S:1295 E:1297 ||| .
Although  ||| S:1297 E:1306 ||| IN
the  ||| S:1306 E:1310 ||| DT
studies  ||| S:1310 E:1318 ||| NNS
reviewed  ||| S:1318 E:1327 ||| VBN
have  ||| S:1327 E:1332 ||| VBP
limitations  ||| S:1332 E:1344 ||| NNS
and ||| S:1344 E:1347 ||| CC
,  ||| S:1347 E:1349 ||| ,
historically ||| S:1349 E:1361 ||| RB
,  ||| S:1361 E:1363 ||| ,
concerns  ||| S:1363 E:1372 ||| NNS
have  ||| S:1372 E:1377 ||| VBP
been  ||| S:1377 E:1382 ||| VBN
raised  ||| S:1382 E:1389 ||| VBN
about  ||| S:1389 E:1395 ||| IN
the  ||| S:1395 E:1399 ||| DT
role  ||| S:1399 E:1404 ||| NN
of  ||| S:1404 E:1407 ||| IN
folate  ||| S:1407 E:1414 ||| NN
in  ||| S:1414 E:1417 ||| IN
increasing  ||| S:1417 E:1428 ||| VBG
cancer  ||| S:1428 E:1435 ||| NN
risk ||| S:1435 E:1439 ||| NN
,  ||| S:1439 E:1441 ||| ,
masking  ||| S:1441 E:1449 ||| VBG
B ||| S:1449 E:1450 ||| NNP
( ||| S:1450 E:1451 ||| -LRB-
12 ||| S:1451 E:1453 ||| CD
)  ||| S:1453 E:1455 ||| -RRB-
deficiency ||| S:1455 E:1465 ||| NN
,  ||| S:1465 E:1467 ||| ,
and  ||| S:1467 E:1471 ||| CC
worsening  ||| S:1471 E:1481 ||| VBG
depressive  ||| S:1481 E:1492 ||| JJ
symptoms ||| S:1492 E:1500 ||| NNS
,  ||| S:1500 E:1502 ||| ,
folate  ||| S:1502 E:1509 ||| NN
is  ||| S:1509 E:1512 ||| VBZ
generally  ||| S:1512 E:1522 ||| RB
well  ||| S:1522 E:1527 ||| RB
tolerated ||| S:1527 E:1536 ||| JJ
,  ||| S:1536 E:1538 ||| ,
and  ||| S:1538 E:1542 ||| CC
5-MTHF  ||| S:1542 E:1549 ||| NNP
may  ||| S:1549 E:1553 ||| MD
be  ||| S:1553 E:1556 ||| VB
less  ||| S:1556 E:1561 ||| RBR
likely  ||| S:1561 E:1568 ||| JJ
to  ||| S:1568 E:1571 ||| TO
incur  ||| S:1571 E:1577 ||| VB
some  ||| S:1577 E:1582 ||| DT
of  ||| S:1582 E:1585 ||| IN
these  ||| S:1585 E:1591 ||| DT
risks ||| S:1591 E:1596 ||| NNS
.  ||| S:1596 E:1598 ||| .
Several  ||| S:1598 E:1606 ||| JJ
forms  ||| S:1606 E:1612 ||| NNS
of  ||| S:1612 E:1615 ||| IN
folate  ||| S:1615 E:1622 ||| NNS
appear  ||| S:1622 E:1629 ||| VBP
to  ||| S:1629 E:1632 ||| TO
be  ||| S:1632 E:1635 ||| VB
safe  ||| S:1635 E:1640 ||| JJ
and  ||| S:1640 E:1644 ||| CC
efficacious  ||| S:1644 E:1656 ||| NN
in  ||| S:1656 E:1659 ||| IN
some  ||| S:1659 E:1664 ||| DT
individuals  ||| S:1664 E:1676 ||| NNS
with  ||| S:1676 E:1681 ||| IN
major  ||| S:1681 E:1687 ||| JJ
depressive  ||| S:1687 E:1698 ||| JJ
disorder ||| S:1698 E:1706 ||| NN
,  ||| S:1706 E:1708 ||| ,
but  ||| S:1708 E:1712 ||| CC
more  ||| S:1712 E:1717 ||| JJR
information  ||| S:1717 E:1729 ||| NN
is  ||| S:1729 E:1732 ||| VBZ
needed  ||| S:1732 E:1739 ||| VBN
about  ||| S:1739 E:1745 ||| IN
dosage  ||| S:1745 E:1752 ||| NN
and  ||| S:1752 E:1756 ||| CC
populations  ||| S:1756 E:1768 ||| NNS
most  ||| S:1768 E:1773 ||| RBS
suited  ||| S:1773 E:1780 ||| VBN
to  ||| S:1780 E:1783 ||| TO
folate  ||| S:1783 E:1790 ||| VB
therapy ||| S:1790 E:1797 ||| NN
.  ||| S:1797 E:1799 ||| .
